APA (7th ed.) Citation

S, S., A, A. T., N, K., S, K., A, N., & L, D. (2026). Regorafenib modulates glucose metabolism, insulin/GLP-1 signaling, and tau pathology in an STZ-induced model of Alzheimer's disease. Naunyn-Schmiedeberg's archives of pharmacology, 399(2), 2989. https://doi.org/10.1007/s00210-025-04545-6

Chicago Style (17th ed.) Citation

S, Salarinasab, Asgari Taei A, Kaveh N, Karima S, Nikzamir A, and Dargahi L. "Regorafenib Modulates Glucose Metabolism, Insulin/GLP-1 Signaling, and Tau Pathology in an STZ-induced Model of Alzheimer's Disease." Naunyn-Schmiedeberg's Archives of Pharmacology 399, no. 2 (2026): 2989. https://doi.org/10.1007/s00210-025-04545-6.

MLA (9th ed.) Citation

S, Salarinasab, et al. "Regorafenib Modulates Glucose Metabolism, Insulin/GLP-1 Signaling, and Tau Pathology in an STZ-induced Model of Alzheimer's Disease." Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 399, no. 2, 2026, p. 2989, https://doi.org/10.1007/s00210-025-04545-6.